Evidence map›Paper›PMID 32358154›Full record

ArticleThe Journal of rheumatology2021

Flare Rate Thresholds for Patient Assessment of Disease Activity States in Gout.

William Taylor, Nicola Dalbeth, Kenneth G Saag, Jasvinder A Singh, Elizabeth J Rahn, Amy S Mudano, Yi-Hsing Chen, Ching-Tsai Lin, Paul Tan, Worawit Louthreno and 17 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 15 institutions in 13 countries.

William TaylorW. Taylor, MBChB, PhD, FRACP, FAFRM, University of Otago, Wellington, New Zealand.
Nicola DalbethN. Dalbeth, MBChB, MD, FRACP, P. Tan, University of Auckland, Auckland, New Zealand.
Kenneth G SaagK.G. Saag, MD, MSc, E.J. Rahn, PhD, A.S. Mudano, MPH, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Jasvinder A SinghJ.A. Singh, MD, MPH, A.L. Gaffo, MD, MSPH, University of Alabama at Birmingham, and Birmingham VA Medical Center, Birmingham, Alabama, USA.
Elizabeth J RahnK.G. Saag, MD, MSc, E.J. Rahn, PhD, A.S. Mudano, MPH, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Amy S MudanoK.G. Saag, MD, MSc, E.J. Rahn, PhD, A.S. Mudano, MPH, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Yi-Hsing ChenY.H. Chen, MD, PhD, C.T. Lin, MD, Taichung Veterans General Hospital, Taichung, Taiwan.
Ching-Tsai LinY.H. Chen, MD, PhD, C.T. Lin, MD, Taichung Veterans General Hospital, Taichung, Taiwan.
Paul TanN. Dalbeth, MBChB, MD, FRACP, P. Tan, University of Auckland, Auckland, New Zealand.
Worawit LouthrenoW. Louthreno, MD, Chiang Mai University, Chiang Mai, Thailand.
Janitzia Vazquez-MelladoJ. Vazquez-Mellado, MD, PhD, H. Hernández-Llinas, MD, Hospital General de Mexico, Mexico City, Mexico.
Hansel Hernández-LlinasJ. Vazquez-Mellado, MD, PhD, H. Hernández-Llinas, MD, Hospital General de Mexico, Mexico City, Mexico.
Tuhina NeogiT. Neogi, MD, PhD, FRCPC, A.B. Vargas-Santos, MD, Boston University School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0002-9515-1711
Ana B Vargas-SantosT. Neogi, MD, PhD, FRCPC, A.B. Vargas-Santos, MD, Boston University School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0001-5307-0254
Geraldo Castelar-PinheiroG. Castelar-Pinheiro, MD, PhD, R.B. Chaves-Amorim, MD, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
Rodrigo B Chaves-AmorimG. Castelar-Pinheiro, MD, PhD, R.B. Chaves-Amorim, MD, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
Tillman UhligT. Uhlig, MD, H.B. Hammer, MD, PhD, Diakonhjemmet Hospital, Oslo, Norway.
Hilde B HammerT. Uhlig, MD, H.B. Hammer, MD, PhD, Diakonhjemmet Hospital, Oslo, Norway.
Maxim EliseevM. Eliseev, PhD, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia.
Fernando Perez-RuizF. Perez-Ruiz, MD, PhD, Servicio de Reumatologia, Baracaldo, Spain.
Lorenzo CavagnaL. Cavagna, MD, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Geraldine M McCarthyG.M. McCarthy, MD, FRCPI, Mater Misericordiae University Hospital, Dublin, Ireland.
Lisa K StampL.K. Stamp, MBChB, FRACP, PhD, University of Otago-Christchurch, Christchurch, New Zealand.
Martijin GerritsenM. Gerritsen, MD, PhD, Westfries Gasthuis, Hoorn, the Netherlands.
Viktoria FanaV. Fana, MD, Copenhagen Center for Artritis Reserch, Righospitalet Glostrup, Denmark.
Francisca SiveraF. Sivera, MD, PhD, Hospital General Universitario Elda, Elda, Spain.ORCID 0000-0002-3414-1667
Angelo L GaffoJ.A. Singh, MD, MPH, A.L. Gaffo, MD, MSPH, University of Alabama at Birmingham, and Birmingham VA Medical Center, Birmingham, Alabama, USA; agaffo@uabmc.edu.ORCID 0000-0001-7365-7212
University of Alabama at Birmingham · USBoston University · USDiakonhjemmet Hospital · NOHospital General de México · MXTaichung Veterans General Hospital · TWUniversidade do Estado do Rio de Janeiro · BRUniversity of Auckland · NZUniversity of Otago · NZAssociation of Rheumatologists of Russia · RUChiang Mai University · THGlostrup Hospital · DKHospital General de Elda · ESIstituti di Ricovero e Cura a Carattere Scientifico · ITMater Misericordiae University Hospital · IEWestfriesgasthuis · NL

Funding

Research and Evaluation Support Core Unit (RESCU Core)P30AR072571 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI TUHINA NEOGI · 2019 to 2026
$6.9M
The Role of Urate in Knee Osteoarthritis-Related Inflammation, Pathology and PainK24AR070892 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI TUHINA NEOGI · 2017 to 2026
$1.1M
NIAMS NIH HHS K24 AR070892NIAMS NIH HHS P30 AR072571
6 · The paper itself

Abstract

objectiveTo determine the relationship between gout flare rate and self-categorization into remission, low disease activity (LDA), and patient acceptable symptom state (PASS).

methodsPatients with gout self-categorized as remission, LDA, and PASS, and reported number of flares over the preceding 6 and 12 months. Multinomial logistic regression was used to determine the association between being in each disease state (LDA and PASS were combined) and flare count, and self-reported current flare. A distribution-based approach and extended Youden index identified possible flare count thresholds for each state.

resultsInvestigators from 17 countries recruited 512 participants. Remission was associated with a median recalled flare count of zero over both 6 and 12 months. Each recalled flare reduced the likelihood of self-perceived remission compared with being in higher disease activity than LDA/PASS, by 52% for 6 months and 23% for 12 months, and the likelihood of self-perceived LDA/PASS by 15% and 5% for 6 and 12 months, respectively. A threshold of 0 flares in preceding 6 and 12 months was associated with correct classification of self-perceived remission in 58% and 56% of cases, respectively.

conclusionFlares are significantly associated with perceptions of disease activity in gout, and no flares over the prior 6 or 12 months is necessary for most people to self-categorize as being in remission. However, recalled flare counts alone do not correctly classify all patients into self-categorized disease activity states, suggesting that other factors may also contribute to self-perceived gout disease activity.

Indexed as

GoutHumansNeeds AssessmentSelf ReportSymptom Flare Updisease activitygoutremission

Identifiers

PMID32358154
PMCPMC11514052
OpenAlexW3022805996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.